V Gupta1, P K Sahu. 1. Centre for Ophthalmic Sciences, All India Institute of Medical Sciences, New Delhi. gupta_v@mailcity.com
Abstract
PURPOSE: To study the efficacy of topical cyclosporin A in children with vernal keratoconjunctivitis in a prospective randomised double-masked trial. METHODS:Twenty-four children between 5 and 16 years of age were randomly treated with cyclosporin A (CsA) and placebo (vehicle) and followed up for 4 months. RESULTS: Of the 12 patients given CsA, 11 showed symptomatic improvement by 7 days of starting treatment whereas only 3 patients in the placebo group showed mild symptomatic improvement. CONCLUSIONS:Topical cyclosporin is a safe and effective treatment in vernal keratoconjunctivitis.
RCT Entities:
PURPOSE: To study the efficacy of topical cyclosporin A in children with vernal keratoconjunctivitis in a prospective randomised double-masked trial. METHODS: Twenty-four children between 5 and 16 years of age were randomly treated with cyclosporin A (CsA) and placebo (vehicle) and followed up for 4 months. RESULTS: Of the 12 patients given CsA, 11 showed symptomatic improvement by 7 days of starting treatment whereas only 3 patients in the placebo group showed mild symptomatic improvement. CONCLUSIONS: Topical cyclosporin is a safe and effective treatment in vernal keratoconjunctivitis.
Authors: F Mantelli; M S Santos; T Petitti; R Sgrulletta; M Cortes; A Lambiase; S Bonini Journal: Br J Ophthalmol Date: 2007-06-22 Impact factor: 4.638